Company intelligence / Profile preview
Vaxart, Inc.
South San Francisco, California, United Statesvaxart.com ↗
- Ownership
- Public · VXRT
- Employees
- ~109
- Development stage
- Other
01
Overview
Vaxart has completed Phase 1 trials for its oral COVID‑19 vaccine candidate and advanced to Phase 2 studies. Its norovirus and seasonal influenza tablet vaccines are also in or approaching Phase 2. The company’s HPV therapeutic vaccine program represents its first immuno-oncology indication. No products have reached commercialization yet; all programs remain in clinical development.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Oral recombinant vaccines (tablet form)Adenovirus vector-based vaccines
- Industry
- Biotech
02
Drug pipeline
44 assets43 more assets in the full pipeline.
03
Financials
- Market cap
- $89.8M
- Total revenue
- $237.3M
- Enterprise value
- $31.5M
Beyond the preview
Go deeper on Vaxart, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxart, Inc..